Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | KDM4A | O75164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | USP1 | O94782 | 12/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | TSPO | P30536 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18865609 | 0.82 | USP1 (0.67) | USP1 | |
| SCHEMBL29691093 | 0.82 | USP1 (0.67) | USP1 | |
| SCHEMBL29651071 | 0.81 | GSK3B (0.64) | HPGDKDM4EALDH1A1TSHRHTT | |
| SCHEMBL18883092 | 0.78 | USP1 (0.77) | USP1 | |
| SCHEMBL30328166 | 0.77 | HPGD (0.38) | HPGDHTTHSD17B10USP1 | |
| SCHEMBL4184836 | 0.77 | PDE4A (0.43) | HPGDTSHRHTTNPSR1HSD17B10 | |
| SCHEMBL30677051 | 0.76 | USP1 (0.48) | USP1 | |
| SCHEMBL23966211 | 0.76 | USP1 (0.42) | USP1 | |
| SCHEMBL29691169 | 0.76 | USP1 (0.71) | USP1 | |
| SCHEMBL18865596 | 0.76 | USP1 (0.71) | USP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582703-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2013-04-24 | — | — | EP | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| WO-2011157397-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157397-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-12-22 | — | — | WO | disclosed |
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | HPGD 1942/4885KDM4E 1319/4885KDM4A 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.